Patents by Inventor Robert D. Selliah

Robert D. Selliah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic compounds useful as inhibitors of tyrosine kinases
    Patent number: 6844435
    Abstract: Disclosed are novel compounds of formula (I): wherein Ar1, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: January 18, 2005
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Roger John Snow, Donghong A. Gao, Daniel R. Goldberg, Abdelhakim Hammach, Daniel Kuzmich, Tina Marie Morwick, Neil Moss, Anthony S. Prokopowicz, III, Robert D. Selliah, Hidenori Takahashi
  • Heterocyclic compounds useful as inhibitors of tyrosine kinases
    Publication number: 20030207902
    Abstract: Disclosed are novel compounds of formula (I): 1
    Type: Application
    Filed: October 15, 2002
    Publication date: November 6, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Roger John Snow, Donghong A. Gao, Daniel R. Goldberg, Abdelhakim Hammach, Daniel Kuzmich, Tina Marie Morwick, Neil Moss, Anthony S. Prokopowicz, Robert D. Selliah, Hidenori Takahashi
  • Heterocyclic compounds useful as inhibitors of tyrosine kinases
    Patent number: 6489328
    Abstract: Disclosed are novel compounds of formula (I): wherein Ar1, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.
    Type: Grant
    Filed: August 2, 2001
    Date of Patent: December 3, 2002
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Roger John Snow, Donghong A. Gao, Daniel R. Goldberg, Abdelhakim Hammach, Daniel Kuzmich, Tina Marie Morwick, Neil Moss, Anthony S. Prokopowicz, III, Robert D. Selliah, Hidenori Takahashi
  • Heterocyclic compounds useful as inhibitors of tyrosine kinases
    Publication number: 20020119975
    Abstract: Disclosed are novel compounds of formula (I): 1
    Type: Application
    Filed: August 2, 2001
    Publication date: August 29, 2002
    Inventors: Roger John Snow, Donghong A. Gao, Daniel R. Goldberg, Abdelhakim Hammach, Daniel Kuzmich, Tina Marie Morwick, Neil Moss, Anthony S. Prokopowicz, Robert D. Selliah, Hidenori Takahashi
  • Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
    Patent number: 6369102
    Abstract: Substituted tetrahydrofuran analogs of prostaglandins and methods of their use in treating glaucoma and ocular hypertension are disclosed.
    Type: Grant
    Filed: March 6, 2001
    Date of Patent: April 9, 2002
    Assignee: Alcon Manufacturing, Ltd.
    Inventor: Robert D. Selliah
  • Method of prostaglandin synthesis
    Patent number: 6344581
    Abstract: Methods of synthesizing 9-Halo-13,14-dihydroprostaglandins useful in the treatment of glaucoma and ocular hypertension are disclosed. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandins.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: February 5, 2002
    Assignee: Alcon Manufacturing, Ltd.
    Inventors: Raymond E. Conrow, Paul W. Zinke, Peter G. Klimko, Robert D. Selliah
  • Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
    Publication number: 20010029265
    Abstract: Substituted tetrahydrofuran analogs of prostaglandins and methods of their use in treating glaucoma and ocular hypertension are disclosed.
    Type: Application
    Filed: March 6, 2001
    Publication date: October 11, 2001
    Inventor: Robert D. Selliah
  • Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
    Patent number: 6197812
    Abstract: Substituted tetrahydrofuran analogs of prostaglandins and methods of their use in treating glaucoma and ocular hypertension are disclosed.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: March 6, 2001
    Assignee: Alcon Laboratories, Inc.
    Inventors: Robert D. Selliah, Mark R. Hellberg, Peter G. Klimko, Verney L. Sallee, Paul W. Zinke
  • 14-aza prostaglandins for the treatment of glaucoma and ocular hypertension
    Patent number: 6160013
    Abstract: 14-Aza analogs of PGF.sub.2.alpha., PGD.sub.2, and PGE.sub.2 and methods of their use in treating glaucoma and ocular hypertension are disclosed.
    Type: Grant
    Filed: November 30, 1999
    Date of Patent: December 12, 2000
    Assignee: Alcon Laboratories, Inc.
    Inventor: Robert D. Selliah
  • substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
    Patent number: 6025392
    Abstract: Substituted tetrahydrofuran analogs of F-series prostaglandins and methods of their use in treating glaucoma and ocular hypertension are disclosed.
    Type: Grant
    Filed: July 2, 1998
    Date of Patent: February 15, 2000
    Assignee: Alcon Laboratories, Inc.
    Inventors: Robert D. Selliah, Mark R. Hellberg, Peter G. Klimko, Verney L. Sallee, Paul W. Zinke
  • Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
    Patent number: 5994397
    Abstract: Substituted tetrahydrofuran analogs of prostagladins and methods of their use in treating glaucoma and ocular hypertension are disclosed.
    Type: Grant
    Filed: April 4, 1997
    Date of Patent: November 30, 1999
    Assignee: Alcon Laboratories, Inc.
    Inventors: Robert D. Selliah, Peter G. Klimko
  • Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
    Patent number: 5866602
    Abstract: Keto-substituted tetrahydrofuran analogs of prostaglandins and methods of their use in treating glaucoma and ocular hypertension are disclosed.
    Type: Grant
    Filed: June 18, 1997
    Date of Patent: February 2, 1999
    Assignee: Alcon Laboratories, Inc.
    Inventor: Robert D. Selliah
  • 9-oxa prostaglandin analogs as ocular hypotensives
    Patent number: 5814660
    Abstract: Substituted tetrahydrofuran analogs of prostaglandins and methods of their use in treating glaucoma and ocular hypertension are disclosed.
    Type: Grant
    Filed: June 18, 1997
    Date of Patent: September 29, 1998
    Assignee: Alcon Laboratories, Inc.
    Inventor: Robert D. Selliah
  • Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
    Patent number: 5807892
    Abstract: Certain prostaglandin analogues are useful in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandin analogues.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 15, 1998
    Assignee: Alcon Laboratories, Inc.
    Inventors: Peter G. Klimko, Robert D. Selliah, Thomas R. Dean, Mark R. Hellberg, John E. Bishop
  • Use of 9-deoxy prostaglandin derivatives to treat glaucoma
    Patent number: 5698733
    Abstract: Disclosed are 9-deoxyprostaglandins which are useful in the treatment of glaucoma and ocular hypertension. Some of these 9-deoxyprostaglandins are novel. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandins.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 16, 1997
    Assignee: Alcon Laboratories, Inc.
    Inventors: Mark R. Hellberg, Thomas R. Dean, Paul W. Zinke, Robert D. Selliah, John E. Bishop